

The Canadian Journal of Neurological Sciences

Le Journal Canadien des Sciences Neurologiques

SPECIAL FEATURES

● Editorial The Case Report: Clutter or Contribution to Medical Literature? <i>Harvey B. Sarnat and Robert G. Lee</i>	1
● Viewpoint Normality and Disease <i>Donald B. Calne and Joanna S. Calne</i>	3
● 1987 Penfield Lecture Deafferentation Pain in Man and Animals as it Relates to the DREZ Operation <i>Blaine S. Nashold, Jr.</i>	5

ORIGINAL ARTICLES

● Multicore Myopathy: Not Always a Benign Entity <i>Ashfaq Shuaib and others</i>	10
● Tizanidine Versus Baclofen in the Treatment of Spasticity in Patients with Multiple Sclerosis <i>B. Bass and others</i>	15
● Interpretation of Single Band Patterns in CSF Protein Electrophoresis <i>B.H. Bass and others</i>	20
● Gamma-Aminobutyric Acid (GABA) and Sepsis-Related Encephalopathy <i>T.R. Winder and others</i>	23
● Multimodal Evoked Potential Studies in Leukodystrophies of Children <i>L.J. De Meirlier, M.J. Taylor, W.J. Logan</i>	26
● Treatment of Dopaminomimetic Psychosis in Parkinson's Disease with Electroconvulsive Therapy <i>T.A. Hurwitz, D.B. Calne and K. Waterman</i>	32
● Primary Hypothyroidism Presenting as Growth Delay and Pituitary Enlargement <i>John D. Farley, Ellen L. Toth and Edmond A. Ryan</i>	35
● Lymphocytic Adenohypophysitis <i>Michael W. McDermott and others</i>	38
● Harrington Rod Instrumentation: A Cause of Brown-Sequard Syndrome <i>C.B. Van Orman and H.Z. Darwish</i>	44

SPECIAL SUPPLEMENT — Neurosurgical Symposium	47
--	----

(complete Table of Contents page iii)



XXIIIrd Canadian Congress of
Neurological Sciences

June 14-18, 1988

Quebec City, P.Q.

The Official Journal of

The Canadian Neurological Society
The Canadian Neurosurgical Society
The Canadian Society of Clinical Neurophysiologists
The Canadian Association for Child Neurology

Volume 15, No. 1

February 1988



FOR THE VASCULAR HEAD PAIN PUZZLE

"CAFERGOT"
To ABORT acute
vascular headache

"SANDOMIGRAN® DS
PROPHYLAXIS for chronic
recurring vascular headache

SANDOZ®



Complete headache therapy
Sandoz Canada Inc., Dorval, Quebec H9R 4P5

Cafergot contains: ergotamine tartrate/caffeine
Sandomigran DS contains: pizotyline
Full prescribing information available on request.


TM

PAAB
CCPP

PMAC
ACIM

QSI 9000

Take a Closer Look at the Brain



Far more than an EEG!

The QSI 9000 harnesses the power of advanced computer technology to let you "see" events inside your patient's brain. The versatile QSI 9000 can provide **EEG Functions**, **Evoked Potentials**, and move you easily into **Brain Mapping**. And the QSI 9000's comprehensive Normative Data Base allows quick comparison between patient data and normal brain patterns for increased diagnostic accuracy in complex cases.

Enhanced storage and reporting.

Standard storage mediums include floppy, hard, or optical disks for maximum versatility and minimum space requirements for

convenient retrieval of patient records.

High-resolution color printers allow the clinician to prepare detailed diagnostic reports quickly and easily with the QSI 9000.



QSI 9000™

Look Closer.

For more information on QSI 9000 call:

1-800-387-0209

or (416) 449-7050

QSI 9000 is a Registered Trademark of Quantified Signal Imaging Inc. ©Copyright, Quantified Signal Imaging Inc.



Editor/Rédacteur en chef Robert G. Lee *Calgary*

Associate Editors/Rédacteurs associés Yves Lamarre *Montreal* Harvey B. Sarnat *Calgary*

Founding Editor/Fondateur-rédacteur Robert T. Ross *Winnipeg*

Book Review Editor/Rédacteur de critiques de livres T. Peter Seland *Calgary*

Managing Editor/Adjoint administratif Sally A. Gregg *Calgary*

Editorial Board/Conseil Scientifique

Albert J. Aguayo *Montreal*

Henry J.M. Barnett *London*

Larry Becker *Toronto*

Paul Bédard *Quebec*

George Ebers *London*

Guy Geoffroy *Montreal*

William J. Logan *Toronto*

Morton Low *Vancouver*

John Murphy *Toronto*

Thomas J. Murray *Halifax*

André Olivier *Montreal*

Donald Paty *Vancouver*

Sidney J. Peerless *London*

Terry Picton *Ottawa*

Jean Reiher *Sherbrooke*

Leo P. Renaud *Montreal*

Matthew W. Spence *Halifax*

John Stewart *Montreal*

Charles Tator *Toronto*

Simon Verret *Quebec*

Bryce Weir *Edmonton*

Publications Committee/Comité de Rédaction

John Wherrett *Toronto*

Terry Myles *Calgary*

Warren Blume *London*

John Tibbles *Halifax*

The Official Journal of:/La Revue Officielle de:

The Canadian Neurological Society

La Société Canadienne de Neurologie

President/Président — T. Peter Seland

Secretary-Treasurer/ — William McCormick,

Secrétaire-Trésorier Box 2148, Dickson Centre,
Victoria General Hospital,
Halifax, Nova Scotia
B3H 2Y9

The Canadian Society of Clinical Neurophysiologists

La Société Canadienne de Neurophysiologues Clinics

President/Président — R. Gordon Blair

Secretary-Treasurer/ — Werner J. Becker,

Secrétaire-Trésorier 841 Centre Avenue East,
Calgary, Alberta
T2E 0A1

The Canadian Neurosurgical Society

La Société Canadienne de Neurochirurgie

President/Président — Francis E. LeBlanc

Secretary-Treasurer/ — Alain Godon,

Secrétaire-Trésorier 12361 Notre-Dame-des Anges St.,
Montreal, Quebec
H4J 2C3

The Canadian Association for Child Neurology

L'Association Canadienne de Neurologie Pédiatrique

President/Président — Kevin Farrell

Secretary-Treasurer/ — Daniel Keene,

Secrétaire-Trésorier Suite 208, 150 Montreal Road,
Vanier, Ontario
K1L 8H2

Inquiries regarding membership in a particular society should be directed to secretaries, as above.

Si vous désirez être membres, veuillez adresser votre demande au secrétaires.

The Canadian Journal of Neurological Sciences is published quarterly by University of Calgary Press. The annual subscription rate is \$48.00 for Canada and \$48.00US for U.S.A. and elsewhere. Interns, Residents, Pre- and Post-Doctoral Students \$24.00 per annum. Single copies \$15.00 each. All communications and subscriptions should be sent to the Editor, Canadian Journal of Neurological Sciences, Room 1496, Faculty of Medicine, University of Calgary, 3330 Hospital Drive N.W., Calgary, Alberta, Canada T2N 4N1. Telephone: (403) 220-3062. COPYRIGHT © 1988 by THE CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES INC. No part of this journal may be reproduced in any form without the prior permission of The Canadian Journal of Neurological Sciences. Mailed under second class registration number 3307. Postage paid at Calgary, Alberta. This journal is indexed by *Index Medicus*, *Excerpta Medica* and *Current Contents — Clinical Practice and Life Sciences*.

Le Journal Canadien des Sciences Neurologiques est publié trimestriellement par les Presses de l'Université de Calgary. L'abonnement annuel aux Canada est 48 \$CDN; aux Etats-Unis et à l'étranger 48 \$US. Internes, résidents, fellows pré et post-doctoral: \$24.00 par an. Copie individuel 15 \$. Toutes les communications et les abonnements doivent être adressés à l'Éditeur, Journal des Sciences Neurologiques, chambre 1496, Faculté de Médecine, Université de Calgary, 3330 Hospital Drive N.W., Calgary, Alberta T2N 4N1. Téléphone (403) 220-3062. DROITS D'AUTEUR © 1988: THE CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES INC. Aucune partie de ce Journal ne peut être reproduite, sous quelque forme que ce soit, sans la permission préalable du Journal Canadien des Sciences Neurologiques. Posté sous permis de second classe no 3307. Port payé à Calgary, Alberta. Le Journal est cité et indexé dans *Index Medicus*, *Excerpta Medica* et *Current Contents — Clinical Practice and Life Sciences*.

Advertising representative/Représentant de publicité Keith Health Care Communications,
4953 Dundas St. W., Toronto, Ontario, Canada M9A 1B6 — (416) 239-1233

Printer/Imprimeur McAra Printing Limited, 105, 2507 - 12th Street N.E., Calgary, Alberta T2E 7LS

ISSN 0317 - 1671



Table of Contents

SPECIAL FEATURES

Editorial — The Case Report: Clutter or Contribution to Medical Literature?

Harvey B. Sarnat and Robert G. Lee 1

Viewpoint — Normality and Disease

Donald B. Calne and Joanna S. Calne 3

1987 Penfield Lecture — Deafferentation Pain in Man and Animals as it Relates to the DREZ Operation

Blaine S. Nashold, Jr. 5

ORIGINAL ARTICLES

Multicore Myopathy: Not Always a Benign Entity

Ashfaq Shuaib, Justin M.E. Martin, L. Brent Mitchell and A. Keith W. Brownell 10

Tizanidine Versus Baclofen in the Treatment of Spasticity in Patients with Multiple Sclerosis

B. Bass, B. Weinshenker, G.P.A. Rice, J.H. Noseworthy, M.G.P. Cameron, W. Hader, S. Bouchard and G.C. Ebers 15

Interpretation of Single Band Patterns in CSF Protein Electrophoresis

B.H. Bass, H. Armstrong, B. Weinshenker, G.C. Ebers, J.H. Noseworthy and G.P.A. Rice 20

Gamma-Aminobutyric Acid (GABA) and Sepsis-Related Encephalopathy

T.R. Winder, G.Y. Minuk, E.J. Sargeant and T.P. Seland 23

Multimodal Evoked Potential Studies in Leukodystrophies of Children

L.J. De Meirlier, M.J. Taylor, W.J. Logan 26

Treatment of Dopaminomimetic Psychosis in Parkinson's Disease with Electroconvulsive Therapy

T.A. Hurwitz, D.B. Calne and K. Waterman 32

Primary Hypothyroidism Presenting as Growth Delay and Pituitary Enlargement

John D. Farley, Ellen L. Toth and Edmond A. Ryan 35

Lymphocytic Adenohypophysitis

Michael W. McDermott, Donald E. Griesdale, Kenneth Berry and G. Edward Wilkins 38

Harrington Rod Instrumentation: A Cause of Brown-Sequard Syndrome

C.B. Van Orman and H.Z. Darwish 44

SPECIAL SUPPLEMENT — NEUROSURGICAL SYMPOSIUM

Preface — The William S. Keith Visiting Professorship in Neurosurgery

..... 47

Treatment of Syringomyelia with a Syringosubarachnoid Shunt

Charles H. Tator and Carlos Briceno 48

Current Status of Artificial Vision by Electrocortical Stimulation

John P. Girvin 58

Management of Chronic Ventilatory Insufficiency with Electrical Diaphragm Pacing

R. Graham Vanderlinden, Stanley W. Epstein, Robert H. Hyland, Harley S. Smythe and Loren D. Vanderlinden 63

Cochlear Nerve Monitoring During Cerebellopontine Angle Operations

D.W. Rowed, J.M. Nedzelski, M.Z. Cashman, S. Stanton and R.V. Harrison 68

Electrophysiological Monitoring During Acoustic Neuroma and Other Posterior Fossa Surgery

R.D. Linden, C.H. Tator, C. Benedict, D. Charles, V. Mraz and I. Bell 73

Spectral Analysis of the EEG in Craniocerebral Trauma

Richard J. Moulton, Anthony Marmarou, Jacob Ronen, John D. Ward, Sung Choi, Harry A. Lutz, Steven Byrd, Antonio Desalles, Angelo Maset, J. Paul Muizelarr and Harold F. Young 82

CORRESPONDENCE

..... 87

BOOK REVIEWS

..... 89

CALENDAR OF EVENTS

..... 93

ERRATUM

..... 93

ADVERTISER'S INDEX

xviii



**To the parkinsonian patient,
the little things in life make all the difference**



Add
PARLODEL® 
(bromocriptine mesylate)
**Because quality
of life is the issue**

For brief prescribing information see page xix

SANDOZ




A bright outlook for more epileptic patients

Pr Depakene* valproic acid

to control seizures in more patients than ever...

Depakene, a broad-spectrum anticonvulsant, is the drug of choice in absence seizures *with or without tonic-clonic manifestations.*^{1,2} Depakene is highly effective in *generalized tonic-clonic seizures.*^{3,4}


...with fewer side effects than most anticonvulsants

Unlike phenobarbital or phenytoin, Depakene is rarely associated with impaired performance or behavior problems.^{5,6} In a year-long survey of adverse reactions to anticonvulsants,⁷ sodium valproate, alone or in combination, had one of the lowest incidences of side effects.

Pr Epival* divalproex sodium

**the same effectiveness as Depakene,
with less G.I. upset**

Epival, a new form of valproate, is an enteric-coated tablet which is just as effective as Depakene, while minimizing G.I. upset.⁸ Thus, Epival helps reduce the risk of poor compliance caused by gastric irritation.



PHARMACEUTICAL PRODUCTS DIVISION
ABBOTT LABORATORIES, LIMITED
MONTREAL, CANADA

*TM

PAAB

© Abbott Laboratories, Limited

For brief prescribing information see page xxii

The Added Value Of

Benefit from the Added Value of Nicolet Systems

"Tough buyers" realize that getting the lowest price does not guarantee the best value. The added value of our unique Nicolet Systems provides you with the security of:

- Expert training for all Nicolet systems
- Customer service response in two hours or less
- Applications support from our staff of Ph.D.s
- Seminar series featuring world-renowned speakers
- Complete financial packages and alternatives
- Our 18 years of experience in problem-solving instrumentation

Nicolet Pathfinder MEGA

- Internal 8, 16 or 32 channel EP/EEG amplifiers
- Flexible test protocols
- 1.28 megabytes of memory for powerful data analysis
- Topographic Mapping for all clinical/research investigations
- O.R./I.C.U. monitoring for a variety of surgical procedures
- Fully programmable system via MECOL and/or FORTRAN 77



Nicolet BEAM®

- Benchmark data base from childhood to geriatric



Introducing the NEW Nicolet Pathfinder MEGA

- Accurate quantification of patient abnormalities
- Complete physician and technologist training
- Data analysis that matches your pace



Nicolet Electroencephalographs

- 18 or 21 channels
- "Short Menu" allows rapid selection of filters and sensitivity
- Programmable measurement sequences allow automated recordings
- Tailor each montage to your unique requirements



Nicolet Expert Sleep/Wake™ Analyzer

- Cost-effectively analyzes up to four patients simultaneously
- Permits direct validation of analyzed results with raw data
- Performs adaptable analysis of patient's data to accommodate individual variability
- Facilitates detailed analysis of less frequent or short duration events (such as micro-arousals)

Unique Nicolet Systems



Nicolet NIM-2™

- Provides the surgeon with an intraoperative tool to locate and identify a nerve directly in the surgical field
- Continuously monitors EMG activity from muscles innervated by the particular nerve
- Acoustically alerts the surgeon when the particular nerve has been activated
- Contains unique technology to minimize the effects of electrocautery interference



Nicolet Viking

- Unique quantitative capabilities
- Expandable to 8 channels of simultaneous EMG/EP
- Comprehensive, high-quality, integrated reports
- Protocols easily customized by individual users



Nicolet Magnetic Stimulator

- Fast—no electrodes or skin preparation required
- Painless—ideal for children
- Easily stimulates deep structures
- Extensive safety features for both operator and patient
- Easily interfaced to other Nicolet instruments



Electrodes and Supplies

In addition to our complete line of quality systems, Nicolet offers a full line of EEG/EMG/EP electrodes and accessories. For our latest Supplies Catalog and specific brochures on any of our unique Nicolet Systems simply call **TOLL FREE**

Ontario: 1-800-268-2058

Eastern/Western Canada: 1-800-387-3385

In Quebec Call: 514-678-2134

Nicolet Instrument Canada Inc.
1-1200 Aerowood Drive
Mississauga, Ontario
L4W 2S7



Nicolet CA2000

- Comprehensive Evoked Potential and EMG testing
- User-friendly menu operation with 72 sets of user-defined parameters
- Large color screen with optional remote monitors
- Nicolet-engineered to the highest O.R./I.C.U. standards




Nicolet Compact Four

- All Auditory, Visual and Somatosensory Evoked Potentials
- Complete range of EMG protocols
- Full-feature ENG and ENOG testing
- ERG and EOG for total visual testing

Nicolet
INSTRUMENTS OF DISCOVERY

ProductiveAntispastic



Without Therapy.



With Oversedation.

Information for Authors

The Canadian Journal of Neurological Sciences publishes original articles in the clinical and basic neurosciences. Manuscripts are considered for publication with the understanding that, except for identified review articles, they have not been published elsewhere except in abstract form and are not under simultaneous consideration by another publication. Manuscripts should be submitted to:

The Editor
Canadian Journal of Neurological Sciences
Faculty of Medicine,
University of Calgary
3330 Hospital Drive N.W.
Calgary, Alberta T2N 4N1

Manuscripts and all illustrations should be submitted in triplicate. Papers will be accepted in English or French. All papers should be accompanied by an abstract or a résumé of approximately 150 words on a separate page, preferably in both languages, although the Journal will provide the translation if requested. All manuscripts should be double spaced throughout, including references and legends for illustrations. Margins of at least 25 mm should be left on all sides.

For detailed instructions regarding style and layout, authors should refer to "Uniform requirements for manuscripts submitted to biomedical journals". Copies of this document may be obtained by writing to the journal office, but the main points will be summarized here. Articles should be subdivided under conventional headings of "introduction", "methods and materials", "results" and "discussion" but other headings and subheadings will be considered if more suitable for a particular manuscript. A title page should identify the title of the article, authors, name of institution(s) from which the work originated, and the address and telephone number of the author to whom communications should be addressed. Pages of text should be numbered consecutively. Acknowledgements, including recognition of financial support, should be typed on a separate page at the end of the text.

References are to be numbered in the order of citation in the text. Those cited only in tables or in legends for illustrations are numbered in accordance with a sequence established by the first identification in the text of a particular table or illustration. Titles of journals should be abbreviated according to the style used in Index Medicus. References should be complete including the names of the first three authors followed by "et al"

if there are more than three authors, full title, year of publication, volume number, and inclusive pagination for journal articles. Book or chapter references should also include the place of publication and name of the publisher. Examples of correct forms of references follow:

Journals

Poirier LJ, Filion M, Larochelle L, et al. Physiopathology of experimental parkinsonism in the monkey. *Can J Neurol Sci* 1975; 2: 255-263

Chapter in a book

McGeer PL, McGeer EG. Amino acid neurotransmitters. In: Siegel GJ, Albers RW, Agranoff BW, Katzman R, eds. *Basic Neurochemistry*. Boston: Little, Brown & Co, 1981: 233-254

Illustrations should be high quality glossy black-and-white photographic prints, preferably 127 x 173 mm (5 x 7"). Original artwork and radiographs should not be submitted. The additional cost of colour illustration must be borne by the author; quotations are available upon request from the Journal office. All figures should be identified on the back with the author's name and figure number. Letters and arrows applied to the figures to identify particular findings should be professional appliques suitable for publication. Photomicrographs should include a calibration bar with the scale indicated on the figure or in the legend. Legends for illustrations should be typed on a separate page from the illustrations themselves.

Tables should each be on a separate page and be identified with the title or heading. Particular care should be taken in the preparation of tables to ensure that the data are presented in the most clear and precise format. Each column should have a short or abbreviated heading. Place explanatory matter in footnotes, not in the heading. Do not submit tables as photographs.

The SI system (système international d'unités) should be used in reporting all laboratory data, even if originally reported in another system. Temperatures are reported in degrees Celsius. Other measurements should be reported in the metric system. English language text may use either British or American spelling, but should be consistent throughout.

Review articles on selected topics also are published by the Journal. These are usually invited, but unsolicited reviews will be considered. It is suggested that authors intending to submit reviews contact the Editor in advance.

Letters to the Editor are welcome. These should be limited to two double-spaced pages and may include one illustration and a maximum of four references.

Therapy Is a Fine Art.



With Lioresal.

For brief prescribing information see page xxiv

Successful rehabilitation requires both spinal spasticity control and alertness. And that's why Lioresal® stands out.

Lioresal can control painful flexor spasms, but unlike diazepam, oversedation is rarely a problem^(1,2,3).

And it effectively stops most flexor spasms overnight, so patients can sleep naturally.

Now there's two strengths:

Lioresal 10mg to initiate therapy and
Lioresal D.S. 20mg for maintenance.

Considering that Lioresal has an excellent long-term safety profile, it may be your most effective choice for long-term control of spinal spasticity.

Lioresal^(baclofen)

Lioresal 10mg (initiation therapy)
Lioresal D.S. 20mg (maintenance therapy)

Geigy
Mississauga, Ontario
L5J 2W5

PAB
DGF
G-5139

Information aux Auteurs

Le Journal Canadien des Sciences Neurologiques publie des articles originaux dans les sciences neurologiques, cliniques et fondamentales. Les manuscrits ne sont considérés pour publication qu'à la condition expresse, à l'exception des articles de revue clairement identifiés comme tel, qu'ils n'aient pas été publiés ailleurs, sauf sous forme de résumé et qu'ils ne soient pas sous considération simultanée par un autre journal. Les manuscrits doivent être soumis à:

L'Editeur

Journal Canadien des Sciences Neurologiques,
Faculté de Médecine,
Université de Calgary,
3330 Hospital Drive, N.W.,
Calgary, Alberta T2N 4N1

Les manuscrits et toutes les illustrations doivent être soumis en triplicata. Les articles seront acceptés en français ou en anglais. Tous les articles doivent être accompagnés d'un résumé d'environ 150 mots, sur page séparée, préféablement dans les deux langues, quoique le Journal puisse fournir cette traduction sur requête. Les manuscrits doivent être dactylographiés complètement à double interligne y compris les références et les légendes pour illustrations. Des marges d'au moins 25 mm doivent être laissées de tous les côtés.

Pour les conseils plus détaillés sur le style et la présentation du texte, les auteurs doivent se référer au texte intitulé "Règlements uniformes pour les manuscrits soumis aux journaux biomédicaux". On peut obtenir une copie de ce document en écrivant au bureau du Journal, mais en voici les principaux points: Les articles doivent être présentés selon le plan habituel: "Introduction", "Matériel et méthodes", "Résultats" et "Discussion", mais il est possible d'employer d'autres titres ou sous-titres si nécessaire pour un manuscrit en particulier. Sur une page titre séparée on doit identifier le titre de l'article, les auteurs, les institutions d'où origine le travail, ainsi que l'adresse et le numéro de téléphone de l'auteur à qui devront être adressées les communications. Les remerciements, incluant ceux pour l'appui financier, doivent être dactylographiés sur page séparée à la fin du texte. Les références doivent être numérotées dans l'ordre où elles sont citées dans le texte. Celles qui sont citées seulement dans les tableaux ou légendes d'illustrations sont numérotées selon la séquence établie par la première identification dans le texte de ces tableaux ou illustrations particulières. Les titres des Journaux doivent être abrégés selon le style utilisé dans Index Medicus. Les références doivent être complètes, incluant le nom des trois premiers auteurs suivis de "et al.", s'il y a plus de trois auteurs, le titre complet, l'année de publication, le

numéro du volume et les premières et dernières pages de l'article. Les références aux livres et chapitres de livres doivent aussi inclure le lieu de la publication et le nom de la maison d'édition. Les exemples corrects suivants peuvent être utilisés:

Journaux

Poirier LJ, Filion M, Larochelle L, et al. Physiopathology of experimental parkinsonism in the monkey. *Can J Neurol Sci* 1975; 2: 255-263

Chapitre de livre

McGeer PL, McGeer EG, Amino acid neurotransmitters. In: Siegel GJ, Albers RW, Agranoff BW, Katzman R, eds. *Basic Neurochemistry*. Boston: Little, Brown & Co, 1981: 233-254

Les **illustrations** doivent être sur papier brillant de haute qualité et imprimés en blanc et noir, préféablement 127 x 173 mm (5 x 7"). Les illustrations et photographies originales ne doivent pas être soumises. Le coût supplémentaire des illustrations en couleur revient entièrement à l'auteur; les coûts détaillés peuvent être obtenus directement au bureau du Journal. Il faut identifier toutes illustrations en inscrivant au dos le nom de l'auteur et le numéro. Toutes lettres ou flèches appliquées aux illustrations pour identifier un aspect particulier doivent être de qualité professionnelle. Les photomicroographies doivent inclure une barre de calibration dont l'échelle est mentionnée dans la légende. Les légendes des illustrations doivent être dactylographiées sur une page séparée de celles-ci.

Les **tableaux** doivent être sur des pages séparées et être identifiés avec titre. On doit prendre un soin particulier dans la préparation de ces tableaux afin d'assurer que les données soient présentées avec le format le plus clair et le plus précis possible. Chaque colonne doit avoir un court titre. Les explications doivent être placées en dessous du tableau et non en sous-titre. Un tableau ne doit pas être soumis sous forme de photographie.

On doit employer le système international d'unités (SI) pour toutes données de laboratoire, même si celles-ci sont originellement présentées dans un autre système. Les températures doivent être citées en degrés Celsius. Les autres données doivent utiliser le système métrique. Les textes en anglais peuvent utiliser l'orthographe anglaise ou américaine, mais cet usage doit être constant.


Le Journal publie également des **articles de revue** sur des sujets sélectionnés. Ces articles sont généralement sur invitation, mais, à l'occasion, une revue non sollicitée peut être acceptée. Il serait préférable que les auteurs ayant l'intention de soumettre une telle revue contactent d'abord l'Editeur.

Nous accueillons les **lettres à l'Editeur**. Celles-ci doivent se limiter à deux pages, double interligne et peuvent contenir une seule illustration et ne citer qu'un maximum de quatre références.

New Dimension in EEG and Evoked


SEEG

- ★ Advanced electroencephalography and evoked potentials testing
- ★ Up to 32 recording channels
- ★ Software—control using a "mouse"
- ★ Storage of raw and digitally processed EEG on (hard)disk or streaming tape
- ★ Review of EEG in any desired montage
- ★ Software for spectral, spatial and statistical analysis and for specific applications
- ★ Topographic display ("brain-mapping") of all EEG and EP data




NeuroScope

- ★ Unique touch screen control
- ★ Performs up to four-channel auditory, visual and somatosensory evoked potentials
- ★ Can be configured for EEG, CSA and EP Monitoring
- ★ Computer-generated electrode montage including impedance check
- ★ All stimulator functions for VEP, AEP and SEP
- ★ Test results on floppy disk for review and analysis
- ★ Built in thermal printer



Electroencephalography



Quantitative Analysis



DANTEC ELECTRONICS LTD
140 Shorting Road
Scarborough
Ontario M1S 3S6
Canada
Telephone: (416) 298-2091
Telex: 6525137 dantec tor




EEG and EP Monitoring During Carotid Endarterectomy



Evoked Potentials in Brain and Spinal Surgery



NeuroScope



A different quality of calm

*for the child with
Attention Deficit Disorder*

Cylert®

PEMOLINE

Cylert has helped hyperactive children concentrate, become more attentive and work better^{1,2} – but did not suppress their spontaneity.² Unlike methylphenidate, Cylert has not shown any significant effect on blood pressure.³ And if there is a concern about possible abuse, Cylert is a wise choice. There have been no published reports of abuse or dependence and, unlike other stimulants, Cylert is not on the list of controlled drugs.⁴ With fewer adverse effects and less risk of addiction, Cylert can offer the hyperactive child a different quality of calm.



PHARMACEUTICAL PRODUCTS DIVISION
ABBOTT LABORATORIES, LIMITED
MONTREAL, CANADA

*TM

PAAB

For brief prescribing information see page xxi

This news deserves the front page.

The first ever controlled release form of carbamazepine has been announced by Geigy Pharmaceuticals.

Tegretol CR (controlled release), a new and special form of tricyclic carbamazepine, was developed to provide better tolerability plus all the proven efficacy of conventional Tegretol. In fact new [®] Tegretol[®] CR can significantly reduce plasma concentration peaks in a B.I.D. dosage regimen.^{1,2} This can result in a more stable pattern of cognitive functioning.³ New Tegretol CR. Available in breakable 200 mg and 400 mg tablets for easier titration. For further information contact your Geigy representative.

News to act on. For initiating therapy or switching from conventional carbamazepine.

Tegretol[®] CR.
carbamazepine.



G-66010

Geigy
Mississauga, Ontario
L5N 2W5

Counterpoint

1. **cou-** *ku* **nter-** *koint* **point** *poin*t *n.* 1 a: one or more independent melodies added above or below a given melody 2 a: a complementing or contrasting item; opposite b: use of contrast or interplay of elements in a work of art
2. **coun-ter-poise** *koint-poz* *v.* [ME *cointrepose*] 1: to balance or weigh more at

The next generation of EMG technology, today.

Counterpoint represents the start of a new era in electromyograph technology.

A system so powerful and flexible it challenges the very definition of what EMG technology can accomplish.

Imagine. One instrument that virtually does it all. And does it fast and accurately. Thanks in large part to the quality of our electrodes and amplifiers. And because at the heart of the system we've incorporated the most advanced signal processor in the industry.

Combine that power with an impressive range of software applications, and you've got a system ready to handle the most demanding jobs, from spontaneous activity and motor nerve conduction velocity to single fiber EMG and power spectrum analysis. Plus more.

And because we know how important it is for you to concentrate on your patient - we've done everything in our power to make Counterpoint as easy to use as possible. The software is user-friendly, footswitch allows you to conduct investigations - hands free - and the electrode arm can be connected to either side of the control panel for comfortable use for everyone.

But the most surprising news is that Counterpoint is totally open to your needs. Data storage and filing can take place in an IBM Personal System/2 or AT compatible environment, so you'll never be left behind by the advent of new technologies or software developments.

Counterpoint masterfully orchestrates all the possibilities in one system. It promises to satisfy the most demanding EMG specialists in the field, and at the same time, makes your job a whole lot easier. And after all, isn't that the point?


Counterpoint from Dantec. Advanced technology in harmony with man.

Please call or write for more information.



DANTEC

Electromedical and Scientific Equipment Ltd.
140 Shorting Road
Scarborough, Ontario, M1S 3S6
(416) 298-2091




There's a new trend in treating Parkinson's disease.


Enhance the ability to cope with daily living

Dose-related fluctuations in therapeutic efficacy, abnormal movements, on-off phenomena – all such problems which tend to arise during prolonged therapy have been shown to be less severe when the total daily dosage of levodopa is divided into more frequent, smaller doses of 'Prolopa' 50/12.5.¹

Levodopa plasma levels – high dose,
low frequency²



Levodopa plasma levels – low dose
('Prolopa 50/12.5), high frequency²



Changes in plasma levels demonstrate that more frequent, smaller doses of 'Prolopa' may help smooth daily performance for Parkinson patients.

Prescribe 'Prolopa' in low doses from the start of levodopa treatment

A low dose of 'Prolopa' (50/12.5) b.i.d. or t.i.d. initiated and maintained lasting therapeutic benefits for the majority of patients in a two-year study of the elderly with Parkinson's disease. Nausea and vomiting were not significant problems with this regimen.³

Improve compliance

With 'Prolopa' there is no tablet to break when using lower dosages. A 'Prolopa' 50/12.5 capsule provides the entire prescribed low dose. More convenient, easier for a Parkinsonian patient.

And 'Roche' has developed a Parkinson Care Program to assist physicians in the management of patients, available free from Hoffmann-La Roche.

Prolopa®

(levodopa/benserazide) 4:1

Efficacious, and very cost effective⁴



Original Research in Medicine and Chemistry

(xvi)

For brief prescribing information see page xviii

PAAR
CPP